Replies to post #13924 on Moderna Inc (MRNA)

[axelvento]

Company intends to submit Biologic License Application (BLA) for the indication of reversal of lymphopenia in patients receiving standard-of-care chemotherapy and/or radiation and for the treatment of locally advanced or metastatic pancreatic cancer which includes the first-in-class CAR-NK (PD-L1 t-haNK)

https://www.onclive.com/view/nogapendekin-alfa-inbakicept-car-nk-wins-fda-rmat-designation-for-lymphopenia-reversal-in-metastatic-pancreatic-cancer

https://immunitybio.com/immunitybio-receives-fda-rmat-designation-for-anktiva-and-car-nk-for-the-reversal-of-lymphopenia-in-patients-receiving-standard-of-care-chemotherapy-radiotherapy-and-in-treatment-of-multiply-rel/

$home run